Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 28-Feb 2022. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
4696209011 | Dolutegravir and lamivudine and tenofovir only product in oral dose form | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
4696210018 | Product containing only dolutegravir and lamivudine and tenofovir in oral dose form (medicinal product form) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Dolutegravir and lamivudine and tenofovir only product in oral dose form | Is a | Product containing only dolutegravir and lamivudine and tenofovir (medicinal product) | true | Inferred relationship | Some | ||
Dolutegravir and lamivudine and tenofovir only product in oral dose form | Is a | Dolutegravir- and lamivudine- and tenofovir-containing product in oral dose form | true | Inferred relationship | Some | ||
Dolutegravir and lamivudine and tenofovir only product in oral dose form | Has manufactured dose form | Oral dose form | true | Inferred relationship | Some | ||
Dolutegravir and lamivudine and tenofovir only product in oral dose form | Plays role | Antiretroviral therapeutic role | false | Inferred relationship | Some | ||
Dolutegravir and lamivudine and tenofovir only product in oral dose form | Has active ingredient | Lamivudine (substance) | true | Inferred relationship | Some | 1 | |
Dolutegravir and lamivudine and tenofovir only product in oral dose form | Has active ingredient | Tenofovir (substance) | true | Inferred relationship | Some | 2 | |
Dolutegravir and lamivudine and tenofovir only product in oral dose form | Has active ingredient | Dolutegravir | true | Inferred relationship | Some | 3 |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Product containing precisely dolutegravir (as dolutegravir sodium) 50 milligram and lamivudine 300 milligram and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 milligram/1 each conventional release oral tablet (clinical drug) | Is a | True | Dolutegravir and lamivudine and tenofovir only product in oral dose form | Inferred relationship | Some |
This concept is not in any reference sets